Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TYMS | P04818 | 1/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.53 |
| ▸ | TCF4 | P15884 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438978 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL21905328 | 0.85 | NPC1 (0.56) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL30572504 | 0.85 | NPC1 (0.56) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL2008567 | 0.84 | TYMS (0.49) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL12909165 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL21905340 | 0.80 | SCD (0.56) | ALDH1A1MAPTGAAHSD17B10HSP90AA1 | |
| SCHEMBL30572517 | 0.80 | SCD (0.56) | ALDH1A1MAPTGAAHSD17B10HSP90AA1 | |
| SCHEMBL21905325 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL30572500 | 0.80 | ALDH1A1 (0.49) | ALDH1A1MAPTGAAHSD17B10TYMS | |
| SCHEMBL266609 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MAPTGAAHSD17B10HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | claimed |
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | disclosed |
| EP-3608312-B1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | XIAMEN VIVOHEALTHS TECH CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024019541-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 일동제약(주) | 2024-01-25 | — | — | WO | disclosed |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11584722-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| CN-111423417-B | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC医疗公司 | 2022-11-15 | — | — | CN | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-5274094-A | Diseases or conditions mediated by platelet-activating factor; cyclization of a diamino compound with a carboxylic acid | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-12-28 | — | — | US | disclosed |
| EP-0543858-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0543861-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| US-5200412-A | Antiinflammatory agents and antiallergens | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-04-06 | — | — | US | disclosed |
| US-5196440-A | Compounds active as inhibitors of the cholesterol biosynthesis | ZAMBON GROUP S.P.A. (IT) | 1993-03-23 | — | — | US | disclosed |
| US-5180723-A | Hypertensives, bronchodilators, antiedemic agents | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-01-19 | — | — | US | disclosed |
| WO-1992003422-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992003423-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| US-4940800-A | Beazimidazole compounds active as inhibitors of the cholesterol biosynthesis | ZAMBON GROUP S.P.A. (IT) | 1990-07-10 | — | — | US | disclosed |
| EP-0352864-A2 | Compounds active as inhibitors of the cholesterol biosynthesis | ZAMBON GROUP S.p.A. (IT) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | ALDH1A1 137/4885MAPT 82/4885GAA 15/4885 |
| US-11584722-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | ALDH1A1 137/4885MAPT 82/4885GAA 15/4885 |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | ALDH1A1 1803/4885MAPT 4678/4885GAA 3971/4885 |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | ALDOA, IDE, ACAT1 | ALDH1A1 137/4885MAPT 82/4885GAA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.